- Smith & Nephew has been losing share in major joints, but a new cementless knee implant, the Cori robotic system, and an increased focus on ambulatory centers could reverse that.
- Extremities and joint repair offer attractive growth opportunities, as does the Tula ear tube system, while the wound care business offers good returns on capital but not much growth.
- The market isn't giving much credit for Smith & Nephew's likely margin improvements in 2021-2023, let alone longer-term turnaround and self-improvement potential.
For further details see:
Smith & Nephew Leveraged To Post-Pandemic Normalization And Self-Help